{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:45:09Z","timestamp":1748969109221},"reference-count":13,"publisher":"Royal College of Psychiatrists","issue":"5","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":7732,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1996,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Stability of neuroleptic medication has been associated with optimal clinical effect and minimal side-effects. Depot administration is assumed to yield better stability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Thirty patients on depot neuroleptic treatment were followed during three years with repeated measurements of plasma level and concurrent ratings of clinical symptoms and side-effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 120 blood samples 35 (29%) measurements were outside \u00b1 2 s.d. measurement error (expected 5%). Perphenazine levels were more variable (46%) than haloperidol (25%) and flupenthixol (12.5%). No relationship was found between side-effect ratings and fluctuations of plasma levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Depot neuroleptic medication does not eliminate a clinically unwanted and sometimes marked variation in plasma level.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.169.5.618","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T05:35:17Z","timestamp":1224048917000},"page":"618-621","source":"Crossref","is-referenced-by-count":16,"title":["Large Variations of Plasma Levels During Maintenance Treatment with Depot Neuroleptics"],"prefix":"10.1192","volume":"169","author":[{"given":"Eva","family":"Tuninger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sten","family":"Levander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000026428_ref11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1176\/ajp.149.4.500","article-title":"Haloperidol plasma levels and clinical response: a therapeutic window relationship","volume":"149","author":"Van Putten","year":"1992","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000026428_ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb00900.x"},{"key":"S0007125000026428_ref12","first-page":"1265","article-title":"Smokers need higher doses of neuroleptic drugs","volume":"19","author":"Vinarov\u00e1","year":"1984","journal-title":"Biological Psychiatry"},{"key":"S0007125000026428_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"S0007125000026428_ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800250095013"},{"key":"S0007125000026428_ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198208053070607"},{"key":"S0007125000026428_ref7","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199510000-00005"},{"key":"S0007125000026428_ref3","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"S0007125000026428_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/19.1.155"},{"key":"S0007125000026428_ref8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/ajp.152.2.173","article-title":"D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate","volume":"152","author":"Nyberg","year":"1995","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000026428_ref1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1987"},{"key":"S0007125000026428_ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820050018002"},{"key":"S0007125000026428_ref10","first-page":"982","article-title":"Bioavailability and clinical effect of two different concentrations of haloperidol decanoate","volume":"31","author":"Suy","year":"1982","journal-title":"Current Therapeutic Research"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000026428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T20:12:14Z","timestamp":1557691934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000026428\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,11]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1996,11]]}},"alternative-id":["S0007125000026428"],"URL":"https:\/\/doi.org\/10.1192\/bjp.169.5.618","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,11]]}}}